Article Abstract

A TITAN step forward: apalutamide for metastatic castration-sensitive prostate cancer

Authors: Daniel Hyuck-Min Kwon, Terence Friedlander

Abstract

Metastatic prostate cancer, which presents as either de novo (4–5% of cases) or as a recurrence following definitive therapy for localized disease, has historically been treated with androgen deprivation therapy (ADT) alone. Although 90% of men initially respond to ADT, almost all eventually become castration-resistant and develop progression of their disease.

Article Options

Download Citation